Compare RVYL & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | PPBT |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 7.5M |
| IPO Year | N/A | N/A |
| Metric | RVYL | PPBT |
|---|---|---|
| Price | $0.28 | $0.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 784.3K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.50 | N/A |
| 52 Week Low | $0.25 | $0.53 |
| 52 Week High | $2.33 | $5.20 |
| Indicator | RVYL | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 45.41 |
| Support Level | $0.31 | $0.78 |
| Resistance Level | $0.35 | $0.87 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 1.91 | 17.49 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.